Skip to main content
Equibles

WINDLAS · Windlas Biotech Limited · Documents

Use WINDLAS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WINDLAS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,001.45 INR -11.75 (-1.16%) At close · Nov 13
Rebalance outlook locked
Market Cap
20.67B INR
Shares
20.64M
Volume · Nov 13 70.29K Avg daily vol (3M) 148.05K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 6, 2026
2026
Nov 6
Earnings call
Revenue crosses INR500 crores as CDMO grows 34%

Windlas Biotech Limited reported H1 FY27 revenue of INR512 crores, up 18%, with Q2 revenue rising 19% to INR264 crores. CDMO revenue grew 34% to INR215 crores, while Plant 6 began commercialization in September 2026.

4 source passages
Ladies and gentlemen, good day and welcome to the Q2 and H1 FY27 Earnings Conference Call for Windlas Biotech Limited. In H1 FY27, Windlas crossed INR500 crores milestone in half-yearly revenue for the first time. Revenue grew 19% y-o-y to INR264 crores in Q2, and 18% to INR512 crores in H1 of FY27. Generic formulation CDMO remains our anchor. Customers have entrusted us with a larger share of their portfolios and new products, which lifted Q2 FY27 revenue by 34% to INR215 crores, and H1 FY27 revenue by 32% to INR422 crores. In line with our long-term growth aspirations, the commercialization of Plant 6 in September 2026 marks a key addition to our manufacturing infrastructure. Open the document at this passage
Showing 1–3 of 3 documents